Close Menu
Home › Veracyte Q2 Revenues Rise 23 Percent

Veracyte Q2 Revenues Rise 23 Percent

Aug 03, 2016

This article has been updated to clarify Veracyte's copromotion arrangement with Sanofi Genzyme.

NEW YORK (GenomeWeb) – Veracyte announced after the close of the market Wednesday a 23 percent rise in its second quarter revenues as the company continued to experience increased demand for its Afirma gene expression classifier thyroid test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jul
23
Featured Webinar

A Novel Quality Improvement Model to Support Molecular Testing of Oncology Patients

Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
25
Featured Webinar

Cell-free DNA Testing for Fetal Aneuploidy: Lessons Learned and Implications for Clinical Practice

This webinar will discuss the evolution of fetal aneuploidy screening and the most recent evidence around the implementation of prenatal cell-free DNA testing in clinical practice.

What's Popular?

In Molecular Diagnostics

  1. Eurofins Acquires Transplant Genomics

  2. FDNA, PerkinElmer Form Genetic Testing Technology Alliance

  3. Liquid Biopsy Monitoring, Surveillance Efforts Accelerate Across Cancer Types and Technologies

    Premium

  4. Menarini to Distribute PlexBio IntelliPlex MDx System

  5. Liquid Biopsy Assay From MSKCC Approved by New York State

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb LLC.  All Rights Reserved.